The aspirin–clopidogrel combination is the current gold standard antiplatelet regimen
following percutaneous coronary intervention and for the treatment of acute coronary …

Dual antiplatelet therapy (DAPT), or the combination of aspirin and an oral inhibitor of the
platelet P2Y12 receptor, is indicated in acute coronary syndromes (ACS) and after …

The synergistic blockade of the key platelet signaling pathways of cyclooxygenase-1
blockade and P2Y12 signaling by combining aspirin plus a potent P2Y12 inhibitor …

The current standard of antiplatelet therapy of patients after myocardial infarction includes
the P2Y 12 receptor antagonists clopidogrel, prasugrel or ticagrelor. This study aimed to …

Dual antiplatelet therapy consisting of one of the P2Y12 receptor inhibitors in conjunction
with aspirin is the mainstay of treatment for patients with acute coronary syndromes (ACS) …

Background: Pharmacological properties of the currently available P2Y12 receptor
antagonists differ significantly and lead to different degrees of platelets inhibition and …

Introduction Dual antiplatelet therapy (DAPT), including potent P2Y12 inhibition after ST-
elevation myocardial infarction (STEMI) is recommended in clinical guidelines. However …

The thienopyridine P2Y 12 receptor antagonists clopidogrel and prasugrel prevent arterial
thrombosis and are routinely used following percutaneous coronary intervention. However …

Clinical manifestations of atherothrombotic disease, such as acute coronary syndromes,
cerebrovascular events, and peripheral arterial disease, are major causes of mortality and …

Oral platelet P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor), used in adjunct to
aspirin, are key in reducing ischemic events among patients with acute coronary syndrome …